Senator Durbin Expresses Disappointment Over NIH Budget Cuts to Medical Research

Durbin's Disappointment with NIH Budget

• senator Dick Durbin expressed personal disappointment regarding proposed budget cuts to the National Institutes of Health (NIH).
• He recalled a decade-old conversation with former NIH Director Francis Collins, who recommended a 5% real growth annually for NIH funding to foster breakthroughs.
• Durbin highlighted bipartisan efforts that increased NIH funding from $30 billion to $48 billion over ten years, an $18 billion increase.

Impact of Proposed Cuts

• The current budget proposal is seen as wiping out the $18 billion increase achieved over the past decade.
• Durbin specifically pointed to proposed cuts of 38% to the National Cancer Institute and 39% to the National Institute of Aging.
• These cuts affect millions of Americans, including the 2 million new cancer cases expected in 2025 and the 7 million people living with Alzheimer's.

Specific Case of Northwestern University

• Durbin cited the case of Northwestern University, which has reportedly not received NIH grants in 11 weeks, with 1,359 awards frozen or terminated.
• This has impacted $81 million in research, including $9 million for clinical trials for various cancers.
• He questioned how these budget decisions reconcile with the reality of research and its role in alleviating suffering and offering hope.

NIH Director's Response

• NIH Director Jay Bhattacharya stated his intention was not to walk away from medical research.
• He acknowledged the budget is a collaboration between Congress and the administration and described the transition as a bumpy time with opportunities for reform.
• Bhattacharya mentioned that decisions regarding Northwestern happened before his tenure but took responsibility, stating the buck stops in his office.

Hope for Resolution

• The Director suggested that university operations during the pandemic may have complicated scientists' work.
• He expressed hope for a resolution with universities regarding paused grants, citing efforts to prevent pauses at Harvard for ongoing clinical trials.
• Durbin reiterated his personal disappointment and the disappointment of those counting on research for hope, emphasizing the significant increase in NIH research over the last decade that has now been wiped out.